Building Evidence During Crisis: Breast Cancer Care Pathways in a Resource-Constrained Setting
Published in Cancer, General & Internal Medicine, and Public Health
Conducting this study required a true multidisciplinary task force involving attending physicians, breast surgery residents, and collaborators from different medical specialties, both during and after the pandemic period. Data collection itself became a major challenge, as clinical workflows were constantly changing and healthcare professionals were simultaneously balancing patient care, surgical backlogs, academic responsibilities, and the emotional burden imposed by the pandemic.
One of the strongest motivations behind this project was the belief that experiences from resource-constrained public healthcare systems also deserve scientific visibility and international discussion. Despite the limitations inherent to retrospective analyses performed in middle-income settings, we believed that documenting the experience of a large public oncology center during the pandemic could provide valuable external perspectives on how cancer care pathways behave under healthcare system stress.
In many ways, this study was also an exercise in resilience — not only in maintaining cancer care during a global crisis, but also in sustaining academic collaboration, clinical research, and scientific production in a setting with limited resources and continuously shifting priorities.
“This experience reinforced our conviction that meaningful clinical research can emerge even under adverse conditions when collaborative academic networks remain active.”
Master of Science from the Department of Obstetrics and Gynecology, Faculty of Medicine, University of São Paulo (FMUSP).
Breast Surgeon (Mastologist) trained at the University of São Paulo (USP - SP) and General Surgeon by the Pontifical Catholic University of São Paulo (PUC - SP).
Holds a Medical Degree from Centro Universitário Lusíada / Faculdade de Ciências Médicas de Santos (FCMS).
His master’s research focused on the impact of the COVID-19 pandemic on the diagnosis and treatment of patients with breast cancer in a public reference center, evaluating how the health crisis affected oncological navigation and clinical outcomes.
Author of publications in the fields of breast surgery, obstetrics, and general surgery.
Instructor of the Advanced Trauma Life Support (ATLS) course by the American College of Surgeons (ACS).
Follow the Topic
-
BMC Cancer
This is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers.
Related Collections
With Collections, you can get published faster and increase your visibility.
Neoadjuvant and adjuvant therapy for gynecologic malignancies
The ongoing research in this field is vital, as it contributes to improving treatment protocols and patient quality of life. Recent breakthroughs have highlighted the significance of personalized treatment approaches, such as targeted therapies and immunotherapies, which have shown promising results in clinical trials. By exploring the optimal sequencing of neoadjuvant and adjuvant therapies, researchers can provide insights into downstaging tumors, minimizing toxicity, and maximizing the overall effectiveness of treatments, leading to better patient outcomes.
Continued exploration and innovation in neoadjuvant and adjuvant therapies hold the potential to transform the management of gynecologic malignancies. Future research may focus on refining treatment regimens, identifying biomarkers for response, and integrating multidisciplinary approaches to optimize surgical and therapeutic outcomes. As we deepen our understanding of tumor heterogeneity and resistance mechanisms, new therapeutic strategies may emerge, offering hope for improved prognosis in patients with these challenging cancers.
- Efficacy of neoadjuvant and adjuvant chemotherapy
- Role of radiation therapy in treatment protocols
- Impact of neoadjuvant vs. adjuvant approaches on fertility and quality of life
- Strategies for downstaging tumors
- Integration of novel therapies in surgical planning
- Resistance mechanisms and strategies for overcoming them
- Role of molecular profiling in guiding therapy
- Clinical trials landscape and future directions
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jul 21, 2026
Glycosylation in cancer: structure, mechanism, and therapy development
BMC Cancer is calling for submissions to our Collection on Glycosylation in cancer: structure, mechanism, and therapy development.
Glycosylation, the enzymatic process that attaches sugars to proteins and lipids, plays a pivotal role in the progression and metastasis of cancer. Aberrant glycosylation patterns are increasingly recognized as key players in tumor biology, influencing cellular interactions, immune evasion, and signaling pathways. These modifications can alter the physical and chemical properties of glycoproteins, thereby affecting cancer cell behavior. Understanding the structural and mechanistic aspects of glycosylation in cancer offers promising avenues for the development of targeted therapies and biomarkers, which could significantly improve patient outcomes.
The significance of glycosylation in cancer research has garnered increasing attention, leading to notable advancements in the field. Recent studies have elucidated the role of specific glycan structures in cancer cell adhesion and metastasis, providing insights that could inform novel therapeutic strategies. Furthermore, advances in glycomics technologies and bioinformatics tools are enabling researchers to map glycosylation changes with unprecedented precision. This growing body of knowledge lays the groundwork for the development of glycan-based therapies and diagnostics, which hold the potential to revolutionize cancer treatment.
Continued exploration of glycosylation in cancer could lead to groundbreaking advancements in both therapeutic and diagnostic applications. The integration of glycomic profiling with genomic and proteomic data may provide a more comprehensive understanding of tumor heterogeneity and evolution. Additionally, as novel glycosylation inhibitors and therapeutics are developed, we may witness a paradigm shift in how we approach cancer treatment, ultimately leading to more personalized and effective strategies for managing this complex disease.
Topics welcome this Collection include, but are not limited to:
Role of glycosylation in immune evasion
Glycan structures as cancer biomarkers
Therapeutic targeting of glycosylation pathways
Advances in glycomics technologies
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Aug 20, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in